Loading...

Member Profile

Home / Members

AP Biosciences Inc.




Chairman
  • Frank Chen
Date Established
  • 2013/05/28
TWSE Stock ID
  • 6945
Phone Number
  • +886-2-2653-2886
Address
  • Rm. 2, 11F, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City 115011, Taiwan
Website Theraputic Fields
  • Immunology
  • Oncology
Product Classification
  • Biologics
  • Technology Platform

AP Biosciences is a development stage biotherapeutic company focusing on novel bispecific antibody drugs for oncology and autoimmune diseases.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2013 Establishment of AP Biosciences, Inc.
   2015 Completion of the fully human OmniMab phage-display antibody library
   2017 Completion of the T-cube bi-specific antibody platform
   2019 Licensing out of AP505 to Tasly Biopharmaceutical for development, production, and marketing rights in China (Now Tasly Pharmaceutical Group Co., Ltd).
   2020 Completion of Phase I clinical trial for IBI302 in China
   2021 Initiation of Patient Enrollment for Phase II Clinical Trial of IBI302
   2022 Approval for the Phase I clinical trial granted by the U.S. FDA and the TFDA for AP203
   2022 Approval for the Phase I clinical trial granted by the NMPA in China for AP505
   2023 Approval for the Phase I clinical trial granted by the U.S. FDA for AP505
   2023 The AP203 Phase I clinical trial has commenced enrollment at China Medical University Hospital
   2023 Publicly traded in Taiwan (6945.TW)
   2023 Initiation of Patient Enrollment for Phase III Clinical Trial of IBI302